Why Market Vectors® Generic Drugs ETF (GNRX), The Only ETF Targeting Generics?

Industry may benefit from ongoing push to lower health care costs

The only ETF offering global exposure to generic drug producers

Positioned to take advantage of the expected growth of biosimilars

• Approximately 60%1 of Americans take prescription drugs — 88%2 of these are generics
• Generics are shaping the future of pharma as demand continues to soar
• GNRX is the only ETF that gives investors access to the global generics industry

Market Vectors® Generic Drugs ETF (GNRX) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Indxx Global Generics & New Pharma Index (IGNRXT), which is intended to track the overall performance of companies that derive a significant proportion of their revenues or that have the potential to derive a significant proportion of their revenues from the generic drug industry, or that have a primary business focus on the generic drug industry.

click to enlarge

click to enlarge

Access Affordable Pharma

Across the globe more people than ever are taking prescription drugs, contributing to the rising costs of health care. Consumers, insurance companies, and governments are helping to fuel the growth of the generic drug industry as it often provides them with a lower cost alternative to brand name pharmaceuticals. Generics account for 88% of all prescriptions in the U.S.1, 55% in the EU2, and 47% in Japan3. With the Market Vectors Generic Drugs ETF (GNRX) investors can specifically target global generics manufacturers in their investment portfolios.

Generics Are Filling Medicine Cabinets Across the U.S.

click to enlarge

For illustrative purposes only. Percentages are approximations. Source: The Journal of American Medical Association, November 3, 2015. Generic Pharmaceutical Association 2015 Annual Savings Report.

Access Affordable Pharma

Generics account for 88% of prescriptions in the U.S. and 55% of prescriptions in the EU1.
Spending on pharmaceuticals worldwide is expected to increase to $1.3 trillion by 2018, 52% of this increase is expected to come from generics2. Global population growth, an aging demographic, and improved access to healthcare are expected to drive growth in both developed and emerging markets. Segment of Generic Prescriptions in the U.S.1
Over the past 10 years generic drug prescriptons in the U.S. have increased ~54%

click to enlarge

Recently generic drug makers have seen increased investor interest as many brand name drug makers lost patent protections (the “patent cliff”). The next stage of growth is expected to come from hard-to-copy biosimilars, biobetters and supergenerics as government policymakers and insurers continue to seek lower cost drug options for consumers.

Generics Defining the Future of Pharma

Increased global pharmaceutical spending and the drive for lower health care costs have supported demand for generics. Generic drug makers may also see new revenue opportunities from expiring patents on branded drugs and from new classes of generics, such as biosimilars, which provide the potential for higher margins.

Investment Case

The Only ETF Targeting Generics

Market Vectors Generic Drugs ETF (GNRX) is the only ETF specifically targeting the generic drug space by seeking to track an index of global generic drug manufacturers.

GNRX Details

Why GNRX?
• Approximately 60%1 of Americans take prescription drugs — 88%2 of these are generics
• Generics are shaping the future of pharma as demand continues to soar
• GNRX is the only ETF that gives investors access to the global generics industry

Introduction to Generics and Biosimilars

IMPORTANT DISCLOSURES

An investment in the Fund may be subject to risks which include, among others, the development, protection and exploitation of intellectual property rights, expiration of patents and inability to enforce intellectual property rights, significant costs associated with research and development and speculation that those investments will result in profitable products, arduous regulatory approval processes, rapid and significant technological change, uncertainty of reimbursement status by third-party payers such as Medicare, Medicaid, and private health insurance plans. Foreign and emerging markets investments are subject to risks, which include changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations, changes in currency exchange rates, unstable governments, and limited trading capacity which may make these investments volatile in price or difficult to trade. Medium-capitalization companies may be subject to elevated risks. The Fund’s assets may be concentrated in a particular sector and may be subject to more risk than investments in a diverse group of sectors.

Indxx Global Generics & New Pharma Index (the ”Index”) is the exclusive property of Indxx, LLC. Indxx, LLC uses its best efforts to ensure that the Index is calculated correctly. Indxx, LLC has no obligation to point out errors in the Index to third parties. Market Vectors Generic Drugs ETF is not sponsored, endorsed, sold or promoted by Indxx, LLC and Indxx, LLC makes no representation regarding the advisability of investing in Market Vectors Generic Drugs ETF.

Fund shares are not individually redeemable and will be issued and redeemed at their ”Net Asset Value” (NAV) only through certain authorized broker-dealers in large, specified blocks of shares called creation units and otherwise can be bought and sold only through exchange trading. Creation units are issued and redeemed principally in kind. Shares may trade at a premium or discount to their NAV in the secondary market.

Investing involves substantial risk and high volatility, including possible loss of principal. An investor should consider the investment objective, risks, charges and expenses of the Fund carefully before investing. To obtain a prospectus and summary prospectus, which contains this and other information call 800.826.2333 or visit http://www.vaneck.com/market-vectors. Please read the prospectus and summary prospectus carefully before investing.

Van Eck Securities Corporation
666 Third Avenue
New York, NY 10017
800.826.2333

This message is intended only for the personal and confidential use of the designated recipient. If you are not the intended recipient of this message you are hereby notified that any review, dissemination, distribution, or copying of this message is strictly prohibited. This communication is for informational purposes only and should not be regarded as an offer to sell or as a solicitation of an offer to buy any financial product, an official confirmation of any transaction, or as an official statement of Van Eck Global or any of its subsidiaries. Email transmissions cannot be guaranteed to be secure or error-free. Therefore we do not represent that this information is complete or accurate and it should not be relied upon as such. All information is subject to change without notice. All emails at Van Eck Global are, in accordance with Firm policy, to be used for Van Eck Global’s business purposes only. Emails sent from or to the Firm are subject to review by the Firm in accordance with the Firm’s procedure for the review of correspondence.

© Van Eck Global. All rights reserved